Article / BioRxivArticle / BioRxivArticle / BioRxivArticle / BioRxiv
  • RESEARCH CENTERS
  • CORE FACILITIES
    • Advanced Microscopy
    • Cell Culture
    • Molecular Cell Biology
    • Proteomics
    • Drug Discovery
    • Bioinformatics
    • Biomaterials
    • Electrophysiology and Behavior
    • Cognitive Neuroscience
    • Animal House
  • PEOPLE
    • Administration
    • Research Staff
    • Students
  • SERVICES
    • Analytical Services
    • Imaging Services
      • Microscopic Imaging
      • In Vivo Imaging
  • EDUCATION
    • Critical Mind
    • InFocus
    • SABITALKS
    • SABITA Podcast
  • ABOUT US
  • RESEARCH CENTERS
  • CORE FACILITIES
    • Advanced Microscopy
    • Cell Culture
    • Molecular Cell Biology
    • Proteomics
    • Drug Discovery
    • Bioinformatics
    • Biomaterials
    • Electrophysiology and Behavior
    • Cognitive Neuroscience
    • Animal House
  • PEOPLE
    • Administration
    • Research Staff
    • Students
  • SERVICES
    • Analytical Services
    • Imaging Services
  • EDUCATION
    • Critical Mind
    • InFocus
    • SABITALKS
    • SABITA Podcast
  • ABOUT US

Article / BioRxiv

Immunoreactivity Against SLC3A2 in High Grade Gliomas Displays Positive Correlation with Glioblastoma Patient Survival: Potential Target for Glioma Diagnosis and Therapy

Nihal Karakas, Ozan Topcu, Erdem Tuzun, Ozlem Timirci Kahraman, Pulat Akin Sabanci,  Yavuz Aras,  Berrak Yetimler,  Gokcen Unverengil,  Mebrure Bilge Bilgic,  Khalid Shah, Hasan Korkaya
Abstract

Immunity against cancer cells is at the forefront of fight against highly malignant tumors like glioblastomas (GBM). Autoantibodies and their autoantigen cooperators are one of the promising biomarkers linked to the immune responses and have been reported as having an initiative or prognostic role for certain types of paraneoplastic disorders. Nevertheless, immunoreactivity against antigens expressed in GBM are poorly studied. To date, autoantibodies were identified by pursuing targeted approaches. By contrast, in this study, we collected human GBM tissue and sera samples and by applying proteomics analysis, we determined autoantigen candidates for GBM. Subsequent immunohistochemistry and immunoprecipitation experiments revealed that a solute carrier; SLC3A2 is widely overexpressed in GBMs and therefore, immunoreactivity against SLC3A2 is present in high grade GBM, and SLC3A2 expression is altered in GBMs. No antibody interaction was detected in SLC3A2 expressors of low grade gliomas. Furthermore, autoantibody presence was correlated with prolonged survival of GBM patients. Taken together, for the first time, we reported that the SLC3A2 immunoreaction exists in high grade gliomas with a distinct GBM profile. In conclusion, our findings may open up new avenues for our understanding of glioma prognosis in the context of autoimmunity. This may eventually lead to diagnostic and therapeutic inventions that can be utilized for prevention of the disease progression.

Click here for article
Share

SOCIAL MEDIA

SHORTCUT LINKS

  • Administration
  • Contact
  • Corporate Identity
  • Referrence Guide
  • Request Forms
  • Sabita 360°
  • Sabita Society
  • Social

OUR MISSION

Translation of Scientific Findings From Bench to Bedside

  • Read More
  • © 2022 Medipol University | SABITA Research Institute for Health Sciences and Technologies
    [contact-form-7 id="50" title="Contact form 1"]